bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic diseases and cancer. The company's product candidates are based on its lentiviral vector and gene editing technologies, and include treatments for beta-thalassemia, sickle cell disease, cerebral adrenoleukodystrophy, and more. bluebird bio was founded in 1992 and is headquartered in Cambridge, Massachusetts.